Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTBK1 | Q5TCY1 | 11/20 | 0.51 |
| ▸ | TTBK2 | Q6IQ55 | 11/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.49 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.48 |
| ▸ | AKT1 | P31749 | 1/20 | 0.47 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1230817 | 0.86 | TTBK1 (0.54) | TTBK1TTBK2TNNI3K | |
| SCHEMBL27968936 | 0.84 | EGFR (0.45) | TTBK1TTBK2EGFRAURKBINCENP | |
| SCHEMBL1229602 | 0.82 | RET (0.58) | TTBK1TTBK2EGFRAURKBINCENP | |
| SCHEMBL1231324 | 0.81 | TTBK1 (0.45) | TTBK1TTBK2EGFRAURKBINCENP | |
| SCHEMBL1229660 | 0.81 | BTK (0.55) | TTBK1TTBK2EGFRAURKBINCENP | |
| SCHEMBL1229680 | 0.81 | JAK2 (0.44) | AURKBAKT1TNNI3K | |
| SCHEMBL1231261 | 0.80 | TNNI3K (0.47) | TTBK1TTBK2EGFRAURKBINCENP | |
| SCHEMBL1229719 | 0.78 | RET (0.52) | TTBK1TTBK2EGFRAURKBINCENP | |
| SCHEMBL1230583 | 0.77 | TTBK1 (0.46) | TTBK1TTBK2EGFRAURKBINCENP | |
| SCHEMBL1231761 | 0.77 | TTBK1 (0.48) | TTBK1TTBK2EGFRAURKBTNNI3K |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2462141-B1 | NOVEL AZAHETEROCYCLIC COMPOUNDS | MERCK PATENT GMBH (DE) | 2017-09-27 | — | — | EP | claimed |
| US-9023847-B2 | Azaheterocyclic compounds | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | claimed |
| CN-102471338-B | Novel azaheterocyclic compounds | MERCK PATENT GMBH | 2014-07-02 | — | — | CN | claimed |
| US-20120277228-A1 | Novel Azaheterocyclic Compounds | MERCK PATENT GMBH (DE) | 2012-11-01 | — | — | US | claimed |
| EP-2462141-A1 | NOVEL AZAHETEROCYCLIC COMPOUNDS | Merck Patent GmbH (DE) | 2012-06-13 | — | — | EP | claimed |
| EP-2462141-B1 | NOVEL AZAHETEROCYCLIC COMPOUNDS | MERCK PATENT GMBH (DE) | 2017-09-27 | — | — | EP | disclosed |
| US-9023847-B2 | Azaheterocyclic compounds | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| CN-102471338-B | Novel azaheterocyclic compounds | MERCK PATENT GMBH | 2014-07-02 | — | — | CN | disclosed |
| US-20120277228-A1 | Novel Azaheterocyclic Compounds | MERCK PATENT GMBH (DE) | 2012-11-01 | — | — | US | disclosed |
| EP-2462141-A1 | NOVEL AZAHETEROCYCLIC COMPOUNDS | Merck Patent GmbH (DE) | 2012-06-13 | — | — | EP | disclosed |
| WO-2011017009-A1 | NOVEL AZAHETEROCYCLIC COMPOUNDS | MERCK PATENT GMBH (DE) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277228-A1 | Novel Azaheterocyclic Compounds | PCNA, MCL1, MYC | TTBK1 1515/4885TTBK2 1662/4885EGFR 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.